Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Chlorzoxazone
Overview
What is Chlorzoxazone?
Chlorzoxazone USP is a centrally acting skeletal muscle relaxant, available as tablets of 500 mg for oral administration. Its chemical name is 5-Chloro-2-benzoxazolinone, and its structural formula is:
C
H
CINO
MW 169.57
Chlorzoxazone USP is a white or practically white, practically odorless, crystalline powder. Chlorzoxazone is slightly soluble in water; sparingly soluble in alcohol, in isopropyl alcohol, and in methanol; soluble in solutions of alkali hydroxides and ammonia.
Chlorzoxazone tablets contain the inactive ingredients Docusate Sodium, Lactose (hydrous), Magnesium Stearate, Microcrystalline Cellulose, Pregelatinized Starch, Sodium Benzoate, and Sodium Starch Glycolate.
What does Chlorzoxazone look like?
What are the available doses of Chlorzoxazone?
Sorry No records found.
What should I talk to my health care provider before I take Chlorzoxazone?
Sorry No records found
How should I use Chlorzoxazone?
Chlorzoxazone is indicated as an adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions. The mode of action of this drug has not been clearly identified, but may be related to its sedative properties. Chlorzoxazone does not directly relax tense skeletal muscles in man.
What interacts with Chlorzoxazone?
Chlorzoxazone is contraindicated in patients with known intolerance to the drug.
What are the warnings of Chlorzoxazone?
Cyclobenzaprine may enhance the effects of alcohol, barbiturates, and other CNS depressants.
Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.)
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
Usage in Pregnancy
The safe use of chlorzoxazone has not been established with respect to the possible adverse effects upon fetal development. Therefore, it should be used in women of childbearing potential only when, in the judgment of the physician, the potential benefits outweigh the possible risks.
What are the precautions of Chlorzoxazone?
Chlorzoxazone should be used with caution in patients with known allergies or with a history of allergic reactions to drugs. If a sensitivity reaction occurs such as urticaria, redness, or itching of the skin, the drug should be stopped.
If any symptoms suggestive of liver dysfunction are observed, the drug should be discontinued.
What are the side effects of Chlorzoxazone?
Chlorzoxazone containing products are usually well tolerated. It is possible in rare instances that chlorzoxazone may have been associated with gastrointestinal bleeding. Drowsiness, dizziness, lightheadedness, malaise, or over-stimulation may be noted by an occasional patient. Rarely, allergic-type skin rashes, petechiae, or ecchymoses may develop during treatment. Angioneurotic edema or anaphylactic reactions are extremely rare. There is no evidence that the drug will cause renal damage. Rarely, a patient may note discoloration of the urine resulting from a phenolic metabolite of chlorzoxazone. This finding is of no known clinical significance.
To report SUSPECTED ADVERSE EVENTS, contact Actavis at 1-800-272-5525 or FDA at 1-800-FDA-1088 or
for voluntary reporting of adverse reactions.
What should I look out for while using Chlorzoxazone?
Chlorzoxazone is contraindicated in patients with known intolerance to the drug.
Serious (including fatal) hepatocellular toxicity has been reported rarely in patients receiving chlorzoxazone. The mechanism is unknown but appears to be idiosyncratic and unpredictable. Factors predisposing patients to this rare event are not known. Patients should be instructed to report early signs and/or symptoms of hepatotoxicity such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, or jaundice. Chlorzoxazone should be discontinued immediately and a physician consulted if any of these signs or symptoms develop. Chlorzoxazone use should also be discontinued if a patient develops abnormal liver enzymes (e.g., AST, ALT, alkaline phosphatase and bilirubin.)
The concomitant use of alcohol or other central nervous system depressants may have an additive effect.
What might happen if I take too much Chlorzoxazone?
How should I store and handle Chlorzoxazone?
Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Keep tightly closed (protect from moisture). Protect from light.Chlorzoxazone tablets, USP are available as oblong, scored, white tablets debossed with on one side and "39"-"68" on the other side and are packaged in bottles of 10, 20, 24, 28, 30 and 40. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Dispense contents with a child-resistant closure (as required) and in a tight container as defined in the USP/NF.Keep out of the reach of children.Chlorzoxazone tablets, USP are available as oblong, scored, white tablets debossed with on one side and "39"-"68" on the other side and are packaged in bottles of 10, 20, 24, 28, 30 and 40. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Dispense contents with a child-resistant closure (as required) and in a tight container as defined in the USP/NF.Keep out of the reach of children.Chlorzoxazone tablets, USP are available as oblong, scored, white tablets debossed with on one side and "39"-"68" on the other side and are packaged in bottles of 10, 20, 24, 28, 30 and 40. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Dispense contents with a child-resistant closure (as required) and in a tight container as defined in the USP/NF.Keep out of the reach of children.Chlorzoxazone tablets, USP are available as oblong, scored, white tablets debossed with on one side and "39"-"68" on the other side and are packaged in bottles of 10, 20, 24, 28, 30 and 40. Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].Dispense contents with a child-resistant closure (as required) and in a tight container as defined in the USP/NF.Keep out of the reach of children.
